The estimated Net Worth of Scott D Barnes is at least $2.54 millió dollars as of 10 March 2023. Scott Barnes owns over 10,555 units of Staar Surgical Co stock worth over $1,236,951 and over the last 5 years he sold STAA stock worth over $55,294. In addition, he makes $1,246,350 as Chief Medical Officer at Staar Surgical Co.
Sign up
Scott Barnes STAA stock SEC Form 4 insiders trading
Scott has made over 9 trades of the Staar Surgical Co stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 10,555 units of STAA stock worth $319,922 on 10 March 2023.
The largest trade he's ever made was exercising 45,186 units of Staar Surgical Co stock on 16 November 2020 worth over $2,592,321. On average, Scott trades about 8,619 units every 110 days since 2019. As of 10 March 2023 he still owns at least 40,810 units of Staar Surgical Co stock.
You can see the complete history of Scott Barnes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Barnes biography
Dr. Scott D. Barnes M.D. serves as Chief Medical Officer of the Company. Dr. Barnes comes to STAAR after a distinguished 30-year career with the military, retiring at the rank of Colonel. Since 2004, Dr. Barnes has served as Chief of Ophthalmology Services, Womack Army Medical Center, Fort Bragg, North Carolina. Soon after he joined Womack, he was asked to serve as the theater ophthalmology consultant and surgeon in Iraq and Afghanistan during 2005. In 2006, he returned to Womack as Chief of Refractive Surgery and helped to establish the use of ICLs in the Army. In 2008, Colonel Barnes was awarded the Army Surgeon General's A designator, similar to the level of professor at a civilian institution. Dr. Barnes began his medical career in 1986 as a research assistant in the Department of Genetics, Harvard Medical School/Children's Hospital in Boston and in 1991 became a general surgery intern at William Beaumont Army Medical Center. He went on to become a Special Forces (“Green Beret”) Battalion and Group Surgeon as well as the Deputy Surgeon for the US Army Special Operations Command. He completed an ophthalmology residency at the Wilford Hall/Brooke Army Medical Center in San Antonio, Texas in 1998. Colonel Barnes held numerous ophthalmology positions at a number of military bases and was asked to serve as the Deputy Commander for Clinical Services for all combat trauma, medical, veterinary, and dental care in Afghanistan during a 13-month deployment in 2011-2012. Under Colonel Barnes’ direction at Fort Bragg, more than 3,000 ICLs have been implanted in the eyes of our nation's servicemen and women. Dr. Barnes has given more than 200 presentations and lectures as well as led over 30 ophthalmology or refractive surgery research projects. He has been awarded Speaker of the Day at the Royal Hawaiian Eye Meeting ten times as well as numerous other awards and honors at industry meetings.
What is the salary of Scott Barnes?
As the Chief Medical Officer of Staar Surgical Co, the total compensation of Scott Barnes at Staar Surgical Co is $1,246,350. There are 1 executives at Staar Surgical Co getting paid more, with Caren Mason having the highest compensation of $3,616,040.
How old is Scott Barnes?
Scott Barnes is 58, he's been the Chief Medical Officer of Staar Surgical Co since 2017. There are 10 older and 9 younger executives at Staar Surgical Co. The oldest executive at Staar Surgical Co. is John Moore, 76, who is the Independent Director.
What's Scott Barnes's mailing address?
Scott's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Staar Surgical Co
Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal... és Gilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.
What does Staar Surgical Co do?
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
What does Staar Surgical Co's logo look like?
Complete history of Scott Barnes stock trades at Staar Surgical Co
Staar Surgical Co executives and stock owners
Staar Surgical Co executives and other stock owners filed with the SEC include:
-
Caren Mason,
President, Chief Executive Officer, Director -
Scott Barnes,
Chief Medical Officer -
Keith Holliday,
Chief Technology Officer -
Caren L. Mason,
CEO, Pres & Director -
Hans-Martin Blickensdoerfer,
Senior Vice President - Commercial Operations, Direct Markets Europe and China -
Samuel Gesten,
Chief Legal Officer, Corporate Secretary -
Dr. Scott D. Barnes M.D.,
Chief Medical Officer -
James Francese,
Senior Vice President - Commercial Operations, North America and APAC -
Hans-Martin Blickensdoerfer,
Sr. VP of Commercial Operations and Director of Markets - Europe & China -
Dr. Keith Holliday,
Chief Technology Officer -
Patrick F. Williams,
Chief Financial Officer -
Louis Silverman,
Independent Chairman of the Board -
Stephen Farrell,
Independent Director -
John Moore,
Independent Director -
Patrick Williams,
Chief Financial Officer -
Gilbert Kliman,
Director -
Thomas Frinzi,
Director -
Brian Moore,
IR Contact Officer -
Jon Hayashida,
Vice President - Global Clinical and Medical Affairs -
Graydon Hansen,
Chief Manufacturing Officer and Senior Vice President, Global Operations -
Philippe Subrin,
VP of Collamer Lens Manufacturing & GM of Nidau Operations -
Joanne Egamino Ph.D.,
Global Head of Clinical Operations -
James Francese,
Sr. VP of Commercial Operations - North America & APAC -
William Goodmen,
VP of Global HR -
Samuel J. Gesten,
Chief Legal Officer & Corp. Sec. -
Lou Silverman,
Director -
Stephen P Brown,
Vice President & Chief Financi -
Richard A Meier,
Director -
Partners, L.P.Broadwood Cap...,
-
Partners, L.P.Bradsher Neal...,
-
William P Wall,
Director -
David Bailey,
President and CEO -
Robert Studholme,
Senior VP, Operations -
Wei Jiang,
-
Arthur C Butcher,
-
Nathaniel Sisitsky,
General Counsel -
Nicholas T Curtis,
Sr. VP Sales and Marketing -
Paul Hambrick,
Vice President, Operations -
Robert Kenneth Lally,
Vice President, QA/RA -
David L Schlotterbeck,
Director -
James I Farnworth,
VP Reg Affairs & Quality -
Gunther Roepstorff,
President - Domilens GmbH -
John R Gilbert,
Director -
Thomas R Paul,
Vice President - R & D -
John Bily,
Chief Financial Officer -
Volker D Anhaeusser,
Director -
John S Santos,
Sr. VP Planning & Corp Dev -
Jack Steven Roush,
-
Charles P Slacik,
Director -
Robin Hughes,
Vice President, Marketing -
Mark B Logan,
Director -
Barry G Caldwell,
Director -
Don M Bailey,
Director -
Kathryn Tunstall,
Director -
Philippe Subrin,
VP Switzerland OP -
Charles S Kaufman,
V.P. , General Counsel -
Donald J Todd,
President, Asia/Pacific -
Donald L Fagen,
V.P. Sales for N. America -
David R Morrison,
Director -
Craig Felberg,
VP, R&D and Clinical Affairs -
William Walter Goodmen,
Global VP, Human Resources -
Donald Duffy,
Director -
Isamu Kamijo,
President, STAAR Japan Inc. -
K Peony Yu,
Director -
Aimee S Weisner,
-
Magda Michna,
Chief Clinical, Regulatory, -
Warren Foust,
Chief Operating Officer -
Elizabeth Yeu Lin,
-
Lilian Yansheng Zhou,